drugset / Trial / NCT04060511
A Study of HS-10342 in Patients With Advanced Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
HS-10342 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of HS-10342 in Chinese advanced solid tumor patients. Preliminary efficacy will be also investigated in this study.
Timeline
- Start
- 2019-06-19
- Primary completion
- 2020-12-04
- Completion
- 2021-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HS-10342 | Small molecule | 25 mg | Oral |
| Subject | HS-10342 | Small molecule | 50 mg | Oral |
| Subject | HS-10342 | Small molecule | 100 mg | Oral |
| Subject | HS-10342 | Small molecule | 150 mg | Oral |
| Subject | HS-10342 | Small molecule | 200 mg | Oral |
| Subject | HS-10342 | Small molecule | 250 mg | Oral |
| Subject | HS-10342 | Small molecule | 275 mg | Oral |